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Hematopoietic stem cells (HSCs) are the source of all blood lineages,
and HSCs must balance quiescence, self-renewal, and differentiation
to meet lifelong needs for blood cell development. Transformation
of HSCs by the breakpoint cluster region-ABL tyrosine kinase (BCR-
ABL) oncogene causes chronic myelogenous leukemia (CML). The
E-twenty six (ets) transcription factor GA binding protein (GABP) is
a tetrameric transcription factor complex that contains GABPα and
GABPβ proteins. Deletion in bone marrow of Gabpa, the gene that
encodes theDNA-binding component, caused cell cycle arrest in HSCs
and profound loss of hematopoietic progenitor cells. Loss of Gabpα
prevented development of CML, although mice continued to gener-
ate BCR-ABL–expressing Gabpα-null cells for months that were seri-
ally transplantable and contributed to all lineages in secondary
recipients. A bioinformatic screen identiﬁed the serine-threonine ki-
nase protein kinase D2 (PRKD2) as a potential effector of GABP in
HSCs. Prkd2 expression was markedly reduced in Gabpα-null HSCs
and progenitor cells. Reduced expression of PRKD2 or pharmacologic
inhibition decreased cell cycling, andPRKD2 rescuedgrowthofGabpα-
null BCR-ABL–expressing cells. Thus, GABP is required for HSC cell cycle
entry and CML development through its control of PRKD2. This offers
a potential therapeutic target in leukemia.
LSC | cell cycle control | signal transduction | imatinib
Hematopoietic stem cells (HSCs) are the source of all bloodlineages in bone marrow and peripheral blood. HSCs must
balance quiescence, growth, and differentiation to meet lifelong
demands for blood cell development. HSCs give rise to lineage-
committed progenitor cells, yet retain the ability to renew the
HSC pool. Transcription factors affect HSC proliferation, sur-
vival, and differentiation, and are implicated in leukemic trans-
formation of HSCs (1).
Chronic myelogenous leukemia (CML) is a myeloproliferative
neoplasm (MPN) characterized by inﬁltration of bone marrow,
peripheral blood, and viscera by myeloid cells. In CML, reciprocal
translocation of chromosomes 9 and 22 generates the breakpoint
cluster region-ABL tyrosine kinase (BCR-ABL) oncogene. CML
arises in a leukemic stem cell (LSC), which drives the expansion
of granulocytes and their precursors that is the hallmark of this
MPN. BCR-ABL is a constitutively active tyrosine kinase that
activates downstream signal transduction pathways, and inhibition
of BCR-ABL by tyrosine kinase inhibitors (TKIs), such as ima-
tinib, induces hematologic, cytogenetic, and molecular remission
in most patients with CML (2). A mouse model of CML reca-
pitulates aspects of human CML, and mice die within weeks of
transplantation with BCR-ABL–expressing bone marrow (3).
GA binding protein (GABP) is a tetrameric transcription factor
that contains two molecules of GABPα and two molecules of
various GABPβ proteins. GABP is unique among more than two
dozen mammalian E-twenty six (ets) transcription factors because
it is the only obligate multimer, i.e., it is active only when the tet-
ramer is formed. The carboxyl-terminal ets DNA binding domain
of GABPα binds to aminoterminal ankyrin-like repeats of GABPβ,
whereas the transcription activation domain is encoded in the
GABPβ carboxyl terminus. GABP controls expression of genes
that are required for innate and acquired immunity, including
CD18; Elastase, Neutrophil Expressed (ELANE); and α4 integrin
in myeloid cells (4), and interleukin-7 receptor (IL7R) and Pax5 in
lymphocytes (5, 6). GABP also controls expression of genes that
are required for cell cycle control, and for ribosomal and mito-
chondrial biogenesis (4).
GABPA is a unique gene in the human and mouse genomes,
and its product is the only protein that can recruit GABPβ to
DNA. Deletion of mouse Gabpa inactivates the Gabp complex,
and was shown to cause embryonic lethality (5, 7, 8). Conditional
deletion of Gabpa in mouse embryonic ﬁbroblasts caused pro-
found G1S cell cycle arrest (8). Loss of Gabpα in bone marrow
caused myelodysplasia and profound loss of bone marrow pro-
genitor cells, but reports differ regarding the speciﬁc effects of
Gabpa deletion on HSCs (9, 10).
We show that disruption of Gabpa markedly reduced HSC cell
cycle activity, and that Gabpα loss prevented development of CML
in BCR-ABL–expressing bone marrow. Rather than developing
leukemia, Gabpα-null BCR-ABL+ HSCs continued to generate
mature granulocytes for many months. Gabpα-null BCR-ABL+
HSCs were transplantable into secondary recipients and contributed
to all hematopoietic lineages. A bioinformatic screen implicated the
diacylglycerol- and protein kinase C (PKC)-activated serine-thre-
onine kinase protein kinase D2 (PRKD2) as a potential effector of
GABP in CML. Knockdown or pharmacologic inhibition of
PRKD2 mimicked the effect ofGabpa disruption on the growth of
Gabpα-null HSCs and, conversely, ectopic expression of PRKD2
overcame the growth defect of BCR-ABL–expressing Gabpα-null
HSCs. Thus, Gabpα loss and expression of BCR-ABL achieve
a standoff of sorts, i.e., the proliferative thrust of BCR-ABL par-
tially overcomes the cell cycle arrest of Gabpα loss, whereasGabpa
disruption prevents BCR-ABL–associated CML. This report
describes a cell cycle control mechanism that prevents de-
velopment of leukemia despite continued production of oncogene-
expressing stem cells, and reports PRKD2 as a mediator of BCR-
ABL transformation in CML. These ﬁndings identify a therapeutic
target in CML and strategies to prevent development of leukemia
in oncogene-expressing hematopoietic cells.
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Results
Gabpa Deletion in Bone Marrow Causes Cell Cycle Arrest in HSCs.We
created mice in which loxP recombination sites ﬂank exons that
encode the DNA-binding ets domain (Gabpaﬂ/ﬂ or ﬂoxed mice)
(8). The Mx1Cre transgene was bred into these mice, and injection
with polyinosine-cytosine (pIC) deletes Gabpa in bone marrow
(Gabpa KO or simply KO mice) (9). As controls, Gabpaﬂ/ﬂ lit-
termates that lacked the Mx1Cre transgene were injected with
pIC. Half of the Gabpa KO mice died within 2 wk after the ﬁrst
pIC injection (Fig. 1A). White blood cells, platelets, and hemo-
globin in peripheral blood declined dramatically in KO mice be-
tween days 5 and 14 (Fig. 1B), and microscopic examination
revealed bone marrow hemorrhage with only rare nucleated cells
(Fig. 1C). However, peripheral blood counts in surviving KO mice
recovered (Fig. 1B), and these mice lived for months without
apparent hematologic defects or other abnormalities. Only
Gabpα-replete cells could form in vitro colonies when bone
marrow was sampled 3 wk after pIC injection (Fig. S1). Thus,
rapid overgrowth of bone marrow by the initially small population
of cells that failed to delete Gabpa indicates that Gabpα-replete
bone marrow cells have a growth advantage over Gabpα-null cells.
Bone marrow HSCs are characterized by the absence of lineage
markers (Lin−) and expression of Sca-1 and c-Kit (LSK cells), and
can be distinguished from myeloid progenitor cells, which do not
express Sca-1 (LK cells). Progenitor cells were strikingly decreased
in Gabpα-null bone marrow, yet the overall number of HSCs was
preserved (9). Cell cycle activity of Gabpα-null HSCs wasmarkedly
reduced, and we observed a signiﬁcant increase in G0 cells (Fig.
1D). In contrast, Yu, et al. described loss of HSCs and increased
HSC cell cycle activity following conditional deletion of Gabpa in
bone marrow (10). We developed an experimental strategy that
enabled us to reconcile these divergent reports, by directly com-
paring Gabpα-null and Gabpα-replete bone marrow cells from the
same mouse. We bred the ROSA26 loxP-STOP-loxP YFP trans-
gene intoGabpaﬂ/ﬂMx1Cremice, and induced Cre recombinase to
simultaneously activate expression of yellow ﬂuorescent protein
(YFP) (by deletion of the upstream STOP codon) and delete
Gabpa (Fig. S2A). This experimental approach permitted isolation
of distinct populations of YFP+/Gabpα null HSCs and YFP−/
Gabpα replete cells from bone marrow of single animals. One day
after the second pIC injection, we sorted YFP+ and YFP− bone
marrow cells and conﬁrmed deletion ofGabpa in YFP+HSCs and
retention of the undeleted Gabpaﬂ/ﬂ in YFP− cells (Fig. S2B).
We sought to examine the effect of Gabpa disruption on stem
and progenitor cells. We measured the percentage of HSCs and
progenitor cells among lineage marker negative (Lin−) cells in the
YFP+ and YFP− compartments. As expected in Gabpα-replete
(or WT) bone marrow, the YFP− bone marrow pool contains
more progenitor cells than HSCs (Fig. S2C; see also Fig. 3C and
Fig. S4A). In contrast, the Gabpα-null YFP+ bone marrow pool
exhibited a profound loss of progenitor cells and a relative in-
crease in the percentage of HSCs. Disruption of Gabpa caused
a signiﬁcant reduction in cell cycle activity in HSCs (P < 0.01; Fig.
S2D). Thus, we conﬁrmed the profound loss of bone marrow
progenitor cells, but preservation of primarily quiescent HSCs in
Gabpα-null bone marrow.
Gabp Is Essential for Development of CML. In CML, transformation
of hematopoietic cells by BCR-ABL increases cellular prolifer-
ation and causes massive expansion of the granulocyte pool.
Transplantation ofmice with bonemarrow cells that express BCR-
ABL recapitulates many aspects of CML (3). We previously de-
ﬁned LSCs as BCR-ABL–expressing HSCs (11). Because loss of
Gabpα reducedHSC cell cycle activity, we sought to determine the
effect of Gabpa deletion on development of BCR-ABL–trans-
formed bone marrow. To delete Gabpa in BCR-ABL–expressing
cells, we used a tricistronic retrovirus that expresses BCR-ABL,
Cre recombinase, and green ﬂuorescent protein (GFP) (12) to
infect WT or Gabpaﬂ/ﬂ bone marrow before transplantation (Fig.
2A). Expression of GFP permits identiﬁcation of cells that both
express BCR-ABL and have undergone Cre-mediated deletion of
ﬂoxed Gabpa. Control mice, i.e., mice transplanted with BCR-
ABL-Cre-GFP–infected WT bone marrow, uniformly died with
massive visceral inﬁltration by granulocytes (Fig. 2B). The survival
curve for mice that were transplanted with Gabpaﬂ/ﬂ bone mar-
row was strikingly different. More than two thirds of this cohort
of mice appeared healthy for at least 6 mo beyond trans-
plantation, and never developed an MPN.
Peripheral blood from mice transplanted with BCR-ABL-Cre-
GFP–infected bone marrow contains both GFP+ and GFP− gran-
ulocytes. GFP+ BCR-ABL+ granulocytes are derived from bone
marrow cells that were infected with the retrovirus, whereas GFP−
cells are derived from transplanted bone marrow cells that were
not infected with the retrovirus. We examined peripheral blood
from individual transplanted mice and directly compared GFP+
BCR-ABL+ granulocytes with GFP− cells in the same mouse.
Fourteen days after transplantation of a control mouse with BCR-
ABL-Cre-GFP–infected WT bone marrow, the peripheral blood
contained twice the number of GFP+ BCR-ABL–expressing
granulocytes as normal granulocytes (Fig. 2C), and, by day 21,
GFP+ BCR-ABL–expressing cells dominated the peripheral
blood, and the mouse died soon thereafter from the MPN.
Transplantation with retrovirus-infectedGabpaﬂ/ﬂ bonemarrow
yielded a very different pattern (Fig. 2C). Although GFP+ gran-
ulocytes predominated on day 14, by day 21, GFP+ cells repre-
sented only a minority of granulocytes in the peripheral blood.
Indeed, we observed sustained and stable levels of GFP+ gran-
ulocytes in peripheral blood for months following transplantation
(Fig. 2D). Because each mouse exhibited a distinct level of chi-
merism of GFP+ and GFP− cells, data for each mouse were
C
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Fig. 1. Conditional deletion of Gabpa in mouse
bone marrow causes pancytopenia in association
with reduced HSC cell cycle activity. (A) Kaplan–
Meier survival curve and (B) peripheral white blood
cell (WBC) and platelet counts per cubic millimeter
and hemoglobin (Hgb) concentration (in g/dL) of
control and KO mice following injection with pIC. (C)
Bone sections of control and KO mice 2 wk after pIC
injection, stained with hematoxylin and eosin (H&E)
(magniﬁcation 400×). (D) Flow cytometry after
staining with pyronin Y and Hoechst 33342 for cell
cycle analysis, with percentages of G0, G1, and S/G2/M
indicated (*P < 0.03).
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expressed relative to its own level of chimerism on day 14 (arbi-
trarily set to 100%). We conﬁrmed that peripheral blood GFP+
cells were Gabpα-null (Fig. S3A). We also conﬁrmed that the
GFP+ Gabpα-null bone marrow cells expressed BCR-ABL tran-
script mRNA that was comparable to theGFP+, Gabpα-undeleted
cells (Fig. S3B). Thus, we observed continued and stable pro-
duction of GFP+ BCR-ABL+Gabpα-null granulocytes more than
4 mo after transplantation, without development of CML.
Six weeks after transplantation with BCR-ABL-Cre-GFP–
infected Gabpaﬂ/ﬂ cells, bone marrow was retransplanted into
secondary recipient mice. The majority of GFP+ cells in sec-
ondary recipients were granulocytes, but peripheral blood and
bone marrow also contained small populations of GFP+ B and T
lymphocytes and monocytes (Fig. S3C). Mice secondarily trans-
planted with primary BCR-ABL-Cre–transduced WT bone mar-
row cells develop CML-like disease (13); in contrast, secondary
recipients of primary BCR-ABL-Cre–infected Gabpaﬂ/ﬂ cells did
not develop CML, even after more than 4 mo of additional
observation. The continued production of GFP+ BCR-ABL+
Gabpα-null granulocytes for months after primary transplan-
tation and the generation of GFP+ cells in secondary recipients
indicate that long term (LT) HSCs were the source of BCR-
ABL+ Gabpα-null peripheral blood cells.
Reduced Cell Cycle Activity in Gabpα-Null Cells Prevents CML
Development. We characterized in greater detail the bone mar-
row of individual mice following transplantation with BCR-ABL-
Cre-GFP–infected WT or Gabpaﬂ/ﬂ bone marrow, as demon-
strated in Fig. 3. GFP− cells serve as controls in each mouse and,
as expected in normal bone marrow, the GFP− population
contained more progenitor cells than HSCs (Fig. 3 A, ii, and B, ii,
and Fig. S4A), and comparable numbers of common myeloid
progenitor, granulocyte-monocyte progenitor (GMP), and mega-
karyocyte-erythroid progenitor cells (Fig. 3 A, iv, and B, iv).
Similarly, bone marrow of mice transplanted with BCR-ABL-
Cre-GFP–infected WT cells exhibited more progenitors than
HSCs (Fig. 3 A, iii) and a strong bias of progenitor cells toward
GMP (Fig. 3 A, v). These BCR-ABL+ GFP+ WT HSCs showed
a marked increase in the percentage of Ki-67+, active cycling
cells compared with GFP− HSCs (P < 0.005; Fig. S4B). In con-
trast, bone marrow of mice transplanted with BCR-ABL-Cre-
GFP–infected Gabpaﬂ/ﬂ cells revealed equalization of the pro-
genitor-to-HSC ratio, indicating a signiﬁcant loss of hematopoietic
progenitor cells (Fig. 3 B, iii, and Fig. S4A), which was also seen
in Gabpα-null YFP+ bone marrow (Fig. 3 C, iii, and Fig. S4A).
The Gabpα-null BCR-ABL+ progenitor cells did not exhibit
a bias toward GMP; instead, they showed comparable numbers
of GMP, common myeloid progenitor, and megakaryocyte-ery-
throid progenitor cells (Fig. 3 B, v). These Gabpα-null BCR-
ABL+ cells exhibited neither the excess proliferation seen in WT
BCR-ABL+ cells nor the cell cycle arrest of Gabpα-null YFP+
cells (Fig. S4B). Furthermore, disruption of Gabpa alone only
modestly increased apoptosis in BCR-ABL–transduced LSK
cells, but imatinib treatment of Gabpα-null BCR-ABL+ LSK
cells markedly increased apoptosis, compared with imatinib-
treated Gabpα-undeleted BCR-ABL+ LSK cells (Fig. S4C).
Thus, loss of Gabpα sensitizes BCR-ABL+ LSK cells to TKI-
induced apoptosis. We conclude that Gabpa disruption reduced
cell cycle activity in normal HSCs and in BCR-ABL–transformed
HSCs, and thus prevented the rapid expansion of CML myeloid
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Fig. 2. Gabpa deletion prevents development of CML, but production of BCR-ABL–expressing HSCs continues for months. (A) Schema for infecting bone
marrow cells from Gabpaﬂ/ﬂ or WT donors with MSCV-BCR-ABL-Cre-GFP virus, followed by bone marrow transplantation into irradiated recipient mice, and (B)
the resultant Kaplan–Meier survival curve. (C) Flow cytometry of peripheral blood for Gr1 and GFP expression at days 14 and 21 after transplantation with WT
(+/+) or Gabpaﬂ/ﬂ (ﬂ/ﬂ) bone marrow; percentages of cells in relevant quadrants are indicated. (D) Chimerism analysis of GFP+ Gr1+ peripheral blood cells
following bone marrow transplantation with BCR-ABL-Cre-GFP–infected WT (+/+) or Gabpaﬂ/ﬂ (ﬂ/ﬂ) cells; values (±SEM) for each individual mouse are
expressed relative to the percentage of GFP+ cells in that mouse on day 14, arbitrarily set to 100% (n ≥ 3).
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progenitor cells. The cell cycle arrest accounted for the failure to
develop CML in Gabpα-null bone marrow.
PRKD2 Is an Essential and Direct Target of GABP in HSCs. We used
a bioinformatic approach to identify candidate targets of GABP
that might mediate its effects on cell cycle activity in normal and
in BCR-ABL–transformed HSCs. We compared gene expres-
sion proﬁles of BCR-ABL–transformed mouse HSCs to normal
mouse HSCs and identiﬁed 2,154 genes that were up-regulated
at least twofold (Fig. S5A) (13). Similarly, 4,412 genes were up-
regulated at least twofold in human CD34+ CML cells compared
with normal human CD34+ cells (14). A total of 595 genes were
up-regulated in mouse and human CML data sets. Recently, Yu,
et al. identiﬁed 8,383 genes that were bound by GABP in human
CD34+ blood cells (10). Among the Gabpα-bound genes, 115
were among the 595 genes that were up-regulated in mouse and
human CML.We particularly focused on CML-associated, GABP-
bound genes that are involved in cellular signaling because BCR-
ABL transformation is associated with activation of key signal
transduction pathways.
PRKD2 is a serine-threonine protein kinase that transmits
signals from diacylglycerol and PKC (15). PRKD2 is the major
hematopoietic PRKD isoform. We found that PRKD2 is up-
regulated in mouse and human CML data sets and is bound by
GABP in human HSCs (Fig. S5B). PRKD2 has been identiﬁed as
a susceptibility locus in chronic lymphocytic leukemia (16), but it
has not been implicated in CML or in myeloid cell development.
We measured Prkd2 expression in normal and Gabpα-null
mouse HSCs by using the YFP selection strategy described in
Fig. S2A. Prkd2 mRNA expression was reduced by 60% in
Gabpα-null HSCs (P < 0.04), and 80% in Gabpα-null progenitor
cells (P < 0.01; Fig. S5C). We conclude from chromatin immu-
noprecipitation followed by high-throughput DNA sequencing
(ChIP-Seq) and gene expression data that Prkd2 is a direct
functional target of Gabp in mouse HSCs.
We sought to determine if PRKD2 functionally mediates
Gabp effects in HSCs and in CML. In vitro colony formation in
the absence of added cytokines is characteristic of BCR-ABL–
transformed cells; untransformed hematopoietic cells fail to
grow under these conditions. As expected, in the absence of
added cytokines, WT bone marrow infected with murine stem
cell virus (MSCV)-GFP control virus failed to generate in vitro
colonies (Fig. 4A). As positive controls, WT bone marrow
infected with BCR-ABL-Cre-GFP and Gabpaﬂ/ﬂ bone marrow
infected with BCR-ABL-GFP (which lacks Cre) generated ro-
bust colony growth. However, Gabpaﬂ/ﬂ bone marrow infected
with BCR-ABL-Cre-GFP yielded only rare colonies. Thus, de-
spite expression of BCR-ABL, Gabpα-null cells failed to gen-
erate colonies in the absence of added cytokines.
To determine if PRKD2 could restore growth of Gabpα-null
cells, we used a second “rescue” virus in this assay. As expected,
coinfection with empty MSCV-puro virus failed to restore colony
growth (Fig. 4A). Coinfection with MSCV-Gabpa restored colony
growth to two thirds of the level of the positive controls. The failure
of MSCV-Gabpa to fully restore colony growth of Gabpα-null cells
(P < 0.002) indicates that not all Gabpa-deleted cells were suc-
cessfully coinfected by the rescue virus. Coinfection with MSCV-
PRKD2 signiﬁcantly restored growth compared with MSCV-puro
(P < 0.0005), achieved nearly 40% of the colony number of the
positive controls, and was two thirds as effective in restoring in vitro
colonies as MSCV-Gabpa itself (P < 0.03). We conclude that
PRKD2 partially restored growth of Gabpα-null bonemarrow cells
and thus represents a functionally signiﬁcant mediator of Gabp
effects on BCR-ABL–transformed mouse HSCs.
To further examine the role of PRKD2 in cell cycle control of
CML cells, we used shRNA knockdown of PRKD2 in BCR-ABL–
expressing K562 erythroleukemia cells (Fig. 4B). PRKD2 protein
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was reduced by more than 80% by two different lentiviral shRNA
constructs, compared with scrambled control shRNA. Although
K562 cells express both PRKD1 and PRKD2, shRNA treatment
reduced only PRKD2 expression. Knockdown of PRKD2 signiﬁ-
cantly reduced the percentage of K562 cells in S phase of the cell
cycle (P < 0.02; Fig. 4C). Similarly, knockdown of Prkd2 in BCR-
ABL–transformed primary mouse bone marrow (Fig. S6A) sig-
niﬁcantly reduced colony formation (P < 0.003; Fig. S6B), but did
not affect normal primary mouse bone marrow (Fig. S6C).
PRKD2 transmits signals from diacylglycerol and protein kinase
C, and its phosphorylation is necessary for activation of these
pathways (15). The pyrazine benzamide CRT0066101 inhibits
phosphorylation of all PRKD isoforms (17). Treatment of K562
cells with CRT0066101 reduced phosphorylation of both PRKD1
and PRKD2, but did not affect the protein level of either isoform
(Fig. 4D). Culture of K562 cells in the presence of CRT0066101
caused a dose-dependent reduction of cell growth (Fig. 4E) and
reduced the percentage of S phase cells (P < 0.02; Fig. 4F). Sim-
ilarly, treatment of primary human CML cells with CRT0066101
reduced the percentage of S phase (Fig. S6D andE) and increased
the annexin V+ apoptotic cells, but did not affect apoptosis in
normal human blood cells (Fig. S6F). We conclude that PRKD2 is
a functionally signiﬁcant mediator of the effect of GABP on
proliferation and apoptosis of BCR-ABL–expressing cells.
Discussion
GABP is an ets transcription factor that plays essential roles in
myeloid and lymphoid differentiation and in control of the cell
cycle (4). We now show that disruption of mouse Gabpa caused
pancytopenia as a result of sharply reduced HSC cell cycle ac-
tivity and profound loss of hematopoietic progenitor cells.Gabpa
disruption prevented development of CML from BCR-ABL–
expressing mouse bone marrow, despite ongoing production of
Gabpα-null BCR-ABL+ granulocytes. Thus, Gabpa disruption
prevented leukemia development in this CML model and, con-
versely, BCR-ABL partially overcame the cell cycle arrest in
HSCs associated with Gabpα loss. BCR-ABL+ HSCs were sec-
ondarily transplantable and contributed to all hematopoietic lin-
eages in those recipients. We showed that expression of the serine-
threonine kinase PRKD2 was decreased in Gabpα-null HSCs,
knockdown and pharmacologic inhibition of PRKD2 reduced cell
cycle activity of BCR-ABL transformed HSCs, and reexpression of
PRKD2 partially rescued the growth defects of Gabpα-null bone
marrow cells. We conclude that Gabp is required for HSC cell
cycle activity and that loss of Gabpα blocked development of
CML, in part through its previously unrecognized role in regu-
lating the protein kinase PRKD2. Thus, deletion of Gabpa and
expression of BCR-ABL in HSCs causes a functional standoff that
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balances cell cycle arrest with oncogene-induced hyperproli-
feration and thereby prevents development of leukemia.
Our ﬁndings regarding the loss of cell cycle activity in Gabpα-
null HSCs differ from those of Yu et al. (10), who described
increased HSC cell cycle activity and apoptosis following Gabpa
deletion. How can these divergent ﬁndings be reconciled? Yu
et al. ﬁrst analyzed bone marrow more than 3 wk after initial
Gabpa deletion, and, at that point in time, we found that bone
marrow was overgrown by Gabpα-replete cells. It is unclear if
their analysis reﬂected properties of Gabpα-null bone marrow
cells alone or represented a mixed population of deleted and
undeleted cells. Our present experimental strategy, which used
activation of YFP expression to sort Gabpa-deleted and unde-
leted cells from the same mouse, unambiguously demonstrated
that that Gabpα-null HSCs exhibit reduced cell cycle activity.
Mice that were transplanted with BCR-ABL-Cre-GFP–infec-
ted Gabpaﬂ/ﬂ bone marrow continued to generate GFP+ gran-
ulocytes cells for many months after transplantation. This
indicates that LT-HSCs were targets of BCR-ABL-Cre-GFP
retrovirus infection, because short-term stem cells do not survive
beyond 4 mo. Transplantation into secondary recipients con-
ﬁrmed that, indeed, LT-HSCs were infected by the BCR-ABL
retrovirus, and this conclusion was reinforced by the presence of
GFP+ cells in granulocytes, monocytes, and B and T lymphocytes
of secondary recipients. Despite infection of LT-HSCs, trans-
planted mice developed neither CML nor other leukemia.
PRKD2 is a member of a family of three serine-threonine
kinases that are increasingly implicated in normal cellular func-
tions and in malignant processes. PRKDs are effectors of diac-
ylglycerol-regulated signal transduction pathways and are acti-
vated by phosphorylation through protein PKC-dependent and
PKC-independent pathways. PRKDs are involved in DNA syn-
thesis, gene expression, chromatin organization, cell survival,
differentiation, and other essential cellular functions (15). Over-
expression of PRKD1 or PRKD2 enhanced cell cycle pro-
gression and DNA synthesis in ﬁbroblasts (18), and PRKD2 was
identiﬁed as one of the susceptible loci in human chronic lym-
phocytic leukemia in a genome-wide association study (16).
However, a role for PRKDs has not previously been demon-
strated in HSCs, myeloid cells, or CML. Herein, we report
PRKD2 as a mediator of GABP regulation of cell cycle control
and its involvement in BCR-ABL transformation. CRT0066101 is
a pyrazine benzamide compound that speciﬁcally blocks PRKD1
and PRKD2, but did not suppress PKCα, PKCβ, or PKCe;
MAPK/ERK; c-Raf; c-Src; or c-Abl. CRT0066101 blocked
growth of pancreatic cancer in vivo (17). Targeting multiple ki-
nase pathways in LSCs is essential for improved treatment of
BCR-ABL+ leukemia in mice (11), and CRT0066101 may offer
a therapeutic opportunity in leukemia and other hematopoietic
malignancies.
TKIs induce remissions in the large majority of patients with
CML, but LSCs themselves are resistant to TKIs (19). We and
others have described regulatory pathways that modify devel-
opment of CML, and the growth and differentiation properties of
LSCs. Some pathways, such as PTEN, act as suppressors of CML
progression, whereas others, including HIF1α, are accelerators of
CML (20). This suggests signaling pathways that might be ma-
nipulated to target CML LSCs despite their intrinsic resistance to
TKIs. We previously identiﬁed a leukotriene pathway that is re-
quired by LSCs, but not by normal HSCs (13), and this pathway
offers an opportunity to target LSCs without impairing normal
hematopoiesis. Here we showed that Gabpa disruption prevented
mouse CML development and that targeting GABP sensitized
CML LSCs to imatinib-induced apoptosis, but GABP also plays
essential roles in normal hematopoiesis and thus may not be an
ideal target in the treatment of human CML. However, we iden-
tiﬁed PRKD2 as an essential mediator of the effects of GABP on
CML cells. Knockdown or inhibition of PRKD2 reduced cell cycle
activity and increased apoptosis in mouse or human primary CML
cells, yet did not signiﬁcantly affect normal mouse or human blood
cells. Thus, PRKD2 may also offer a novel therapeutic target in
CML, with the potential to suppress or eradicate LSCs.
In summary, we showed that Gabp is required for cell cycle
activity of HSCs, and that conditional disruption of Gabpa pre-
vented development of CML in a mouse model. Simultaneous
expression of BCR-ABL and loss of Gabpα in HSCs resulted in
a standoff in which cell cycle arrest associated with Gabpa de-
letion was overcome but leukemia failed to develop despite
ongoing production of differentiated BCR-ABL+ cells. We
identiﬁed PRKD2 as a mediator of Gabp in HSC cell cycle
control, apoptosis, and of BCR-ABL signaling. This suggests that
pharmacologic inhibition of PRKD2 may represent a valuable
approach to targeting the LSCs in CML.
Materials and Methods
Animal studies were approved by the University ofMassachusetts Institutional
Animal Care and Use Committee. This use of human material is considered
exempt according to University of Massachusetts Investigation Review Board.
Mice and bone marrow transplantation, analysis of peripheral blood and
mouse tissues, ﬂow cytometry, cell sorting and cell cycle analysis, reverse
transcription, real-time quantitative PCR and immunoblotting, cell culture,
chemicals and retroviral gene transfer, and data analysis are described in
detail in SI Materials and Methods.
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SI Materials and Methods
Mice and Bone Marrow Transplantation. Gabpaﬂ/ﬂ-Mx1Cre mice,
genotyping, polyinosine-cytosine (pIC) injection, and bone mar-
row transplantation were previously described (1), and mice were
bred to Rosa26-loxP-STOP-loxP-YFP mice (Jackson Labs). The
chronic myelogenous leukemia (CML) mouse model was pre-
viously described (2).
Analysis of Peripheral Blood and Mouse Tissues. Complete blood
counts were performed with Hemavet 950 (Drew Scientiﬁc).
Preparation of bone marrow cells was previously described (1).
Bone was ﬁxed with formalin and decalciﬁed with DeCal solution
(Sigma-Aldrich). Tissue sections were prepared by the pathology
core facility of University of Massachusetts Medical School, and
examined with an Eclipse E600 bright-ﬁeld microscope (Nikon).
Flow Cytometry, Cell Sorting, and Cell Cycle Analysis. Flow cytometry
and cell sorting used LSRII and MoFlow (BD Biosciences), and
staining of bone marrow and peripheral blood cells was previously
described (1). For cell cycle analysis, cells were ﬁxed with ethanol
and stained with propidium iodide (Sigma-Aldrich) or with Ki-67
(BD Biosciences).
Reverse Transcription, Real-Time Quantitative PCR, and Immunoblotting.
Reverse transcription, quantitative real-time PCR, and immuno-
blotting were performed as previously described (1). Primary an-
tibodies included β-actin (I-19; Santa Cruz Biotechnology)
and PRKD1, PRKD2, and phospho-PRKD (Cell Signaling
Technology).
Cell Culture, Chemicals, and Retroviral Gene Transfer. Culture of
NIH/3T3, HEK293 (American Type Culture Collection) cells and
mouse bone marrow cells was performed as previously described
(1). Human K562 cells were grown in RPMI/10% (wt/vol) FBS
and CRT0066101 (Cancer Research Technology Discovery
Laboratories, Wolfson Institute for Biomedical Research, Lon-
don WC1E 6BT, United Kingdom) dissolved in DMSO. MTT
assay was performed in a microplate reader (Victor 3 multilabel
count; Perkin-Elmer). In vitro colony-forming assays were per-
formed per manufacturer protocol (StemCell Technologies).
Primary human normal or CML cells were cultured in Iscove
modiﬁed Dulbecco medium (Sigma-Aldrich) supplemented with
a serum substitute BIT, 40 μg/mL low-density lipoproteins, 100
ng/mL recombinant human Flt3-ligand, 100 ng/mL stem cell
factor, 20 ng/mL recombinant human IL-3, 20 ng/mL IL-6, and
20 ng/mL granulocyte colony-stimulating factor (StemCell
Technologies).
Data Analysis. Kaplan–Meier survival curves were generated with
Prism 5 (GraphPad). Flow cytometry data were analyzed with
Diva (BD Biosciences) and FlowJo software (Tree Star). DNA
chromatin immunoprecipitation followed by high-throughput
DNA sequencing (ChIP-Seq) data were analyzed with ChIP-
Seeqer 2.0 software (3). DNA microarray data were analyzed
with SAS 9.1 (SAS Institute). Annotation and demonstration
of ChIP-Seq and microarray data were generated with Bi-
oGPS (4), University of California, Santa Cruz, Genome
Browser (5), and Galaxy (https://main.g2.bx.psu.edu/).
1. Yang ZF, et al. (2011) GABP transcription factor is required for myeloid differentiation,
in part, through its control of Gﬁ-1 expression. Blood 118(8):2243–2253.
2. Peng C, et al. (2010) PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced
leukemias in mice. Blood 115(3):626–635.
3. Giannopoulou EG, Elemento O (2011) An integrated ChIP-seq analysis platform with
customizable workﬂows. BMC Bioinformatics 12:277.
4. Wu C, et al. (2009) BioGPS: an extensible and customizable portal for querying and
organizing gene annotation resources. Genome Biol 10(11):R130.
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Fig. S1. Gabpα is essential for proliferation of bone marrow stem and progenitor cells. Bone marrow cells from Gabpaﬂ/ﬂ-Mx1Cre mice were harvested 21 d
after pIC injection and subjected to in vitro colony forming assay. Genomic DNA were harvested from 100 individual colonies, 10 of which are illustrated here,
and PCR was performed to amplify ﬂoxed (ﬂ) and deleted (Δ) Gabpa alleles. M, DNA size marker, −, no DNA control; +, positive control DNA for indicated
amplicons.
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based on Ki-67 expression.
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Fig. S3. PCR of genomic DNA demonstrates deletion of Gabpa in Gabpaﬂ/ﬂ bone marrow infected with breakpoint cluster region-ABL tyrosine kinase (BCR-ABL)-
Cre-GFP retrovirus, and ﬂow cytometry of peripheral blood from secondary recipient mice. (A) PCR for ﬂoxed (ﬂ), WT (+), and deleted (Δ) Gabpa alleles, and Actin
B control in sorted GFP− and GFP+ peripheral blood granulocytes and in WT (+/+), ﬂoxed (ﬂ/ﬂ), and heterozygous deleted (+/Δ) controls. (B) Quantitative RT-PCR
for BCR-ABL expression in GFP+ Gabpα-undeleted and GFP+ Gabpα-null bone marrow cells. (C) Flow cytometry of peripheral blood for CD11b, B220, and CD3e
expression on GFP− and GFP+ cells 90 d after transplantation of the secondary recipient mice with bone marrow from primary recipient mice transplanted with
BCR-ABL-Cre-GFP–infected Gabpaﬂ/ﬂ (ﬂ/ﬂ) cells; percentages of cells in relevant quadrants are indicated.
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Fig. S5. Bioinformatic analysis of Gabpα-bound genes that are up-regulated in CML. (A) Venn diagram representing numbers of transcripts that are up-
regulated at least twofold in mouse CML stem cells vs. normal HSCs, and in human CD34+ CML cells vs. normal CD34+ cells, overlapping with Gabp-bound
mouse genes from ChIP-Seq. (B) Diagram of human PRKD2 chromatin binding by transcription factors, including GABPα. Red boxes at top indicate binding sites
for GA binding protein (GABP) in human CD34+ blood cells. Color peaks indicate promoter and enhancer locations of histone methylation at H3K4. Black and
gray bars indicate binding sites for individual transcription factors reported with different cell lines. (C) Quantitative RT-PCR for Prkd2 expression in YFP+
(Gabpα-null) and YFP− (undeleted) HSC (LSK) and progenitor cells (LK).
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